<DOC>
	<DOCNO>NCT01016990</DOCNO>
	<brief_summary>RATIONALE : Valproic acid may stop growth cancer cell block enzymes need cell growth . It may also help cancer cell become like normal cell , grow spread slowly . PURPOSE : This phase II trial study well valproic acid work treat patient previously treat non-Hodgkin Lymphoma , Hodgkin lymphoma , chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Valproic Acid Treating Patients With Previously Treated Non-Hodgkin Lymphoma , Hodgkin Lymphoma , Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To determine valproic acid response rate ≥ 20 % patient previously treat relapsed refractory non-Hodgkin lymphoma , Hodgkin lymphoma , chronic lymphocytic leukemia . - To determine treatment valproic acid lead measurable level histone acetylation peripheral blood . OUTLINE : Patients stratify accord disease diagnosis ( indolent non-Hodgkin lymphoma [ NHL ] vs. aggressive NHL Hodgkin lymphoma ) . Valproic acid dos adjust therapeutic level achieve . Patients receive oral valproic acid daily 3 week . Treatment repeat every 3 week least 2 course 2 year absence disease progression unacceptable toxicity . Blood sample collect periodically . Samples analyze valproic acid level ; hyperacetylation ( cause valproic acid N-terminals histone H3 H4 ) via western blot .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse refractory Hodgkin lymphoma ( HL ) , nonHodgkin lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) Patient must evaluable measurable disease Have fail prior treatment , evidence 1 following : Aggressive NHL Failed least 1 regimen contain rituximab CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) ( unless anthracyclines contraindicate ) addition another salvage regimen ( unless determine treat physician patient 's best interest receive valproic acid first relapse ) Hodgkin lymphoma Failed ABVD ( doxorubicin , bleomycin , vinblastine , dacarbazine ) receive salvage chemotherapy least 1 salvage combination regimen Indolent lowgrade lymphoma Failed least 1 combination regimen contain rituximab ( patient intolerant available therapy contraindication eligible study ) No CNS involvement lymphoma PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute granulocyte count ≥ 1,000/mm^3 Platelet count ≥ 50,000/µL AST ALT ≤ 3 time upper limit normal Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 1.5 mg/dL Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : More 14 day since prior anticancer treatment Prior highdose chemotherapy transplant allow No prior valproic acid No concurrent corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>